



Press release
February 19, 2015
Gothenburg

XPS™ approved in Australia

XVIVO Perfusion has received TGA approval of XPS™ (Xvivo Perfusion System). This enables sales of XPS™ in Australia.

With its integrated Hamilton-C2 ventilator and MAQUET CardioHelp centrifugal pump, XPS™ is the market's most flexible and complete platform for EVLP (Ex Vivo Lung Perfusion) and gives the transplantation team full control of the whole process. The XPS™ design means that X-rays and automatic measurement of oxygen and pH can be done while the EVLP evaluation is ongoing. XPS™ has a user-friendly graphic interface, with touchscreen functionality and computer registration of the lung's values throughout the EVLP procedure, which gives data for analysis and evaluation before the final clinical decision is made whether to use the lung.

XVIVO Perfusion's XPS™ and STEEN Solution™ are the only approved products in the USA for evaluation of marginal lungs before lung transplantation. XPS™ and STEEN Solution™ are also CE marked in Europe. Leading clinics in the USA have obtained good clinical results when using XPS™ and sales are beginning to take off in Europe.

Just under two hundred lung transplants are performed each year in Australia. XPS™ with STEEN Solution™ enables more lungs to be used for transplantation, which means that more patients with severe lung disease are given a higher quality and longer life.

"We are very pleased that XPS™ is now available for clinical lung transplantation in Australia. With approval in Australia, XPS™ has now been approved in all the large markets in the world," says Magnus Nilsson, CEO of XVIVO Perfusion.

February 19, 2015
Gothenburg
XVIVO Perfusion AB (publ)

For further information, please contact
Christoffer Rosenblad, CFO, +46 31-788 21 59, christoffer.rosenblad@xvivoperfusion.com

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: +46 31 788 21 50. Fax: +46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com
The information was submitted for publication on February 19, 2015 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.